Distinguished in Leukemia

Jeroen M. Janssen

Radboud UMC
Nijmegen, GE, NL 
Distinguished in Leukemia
Radboud UMC
Nijmegen, GE, NL 
OverviewLocationsClinical Research

Overview

Jeroen Janssen practices in Nijmegen, Netherlands. Mr. Janssen is rated as a Distinguished expert by MediFind in the treatment of Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), Agranulocytosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 132 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 90 articles and participated in 1 clinical trial in the study of Leukemia.

Gender
Male

Locations

Radboud UMC
Nijmegen, GE 6525GA, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase II, Single Arm, Multicenter Study of Nilotinib in Combination With Pegylated Interferon-α2b in Patients With Suboptimal Molecular Response or Stable Detectable Molecular Residual Disease After at Least Two Years of Imatinib Treatment (NordDutchCML009)
A Phase II, Single Arm, Multicenter Study of Nilotinib in Combination With Pegylated Interferon-α2b in Patients With Suboptimal Molecular Response or Stable Detectable Molecular Residual Disease After at Least Two Years of Imatinib Treatment (NordDutchCML009)
Enrollment Status: Terminated
Publish Date: October 12, 2018
Intervention Type: Drug
Study Phase: Phase 2

132 Total Publications

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Journal: Haematologica
Published: July 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Janssen's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile